Aficamten trial brings positive news for patients living with non-obstructive hypertrophic cardiomyopathy

Aficamten attraction was associated with important improvements successful grounds load and workout capableness successful patients with symptomatic non-obstructive hypertrophic cardiomyopathy, according to results presented contiguous successful a Hot Line league astatine ESC Congress 2026 and published simultaneously successful the New England Journal of Medicine.